Moscoso-Solorzano G T, Baltar J M, Seco M, López-Larrea C, Mastroianni-Kirsztajn G, Ortega F
Department of Nephrology, Hospital Central de Asturias, Asturias, Spain.
Transplant Proc. 2007 Dec;39(10):3460-2. doi: 10.1016/j.transproceed.2007.09.043.
Before the highly active antiretroviral therapy (HAART) era, kidney transplantation was not considered an option for patients infected with human immunodeficiency virus (HIV) because of its poor outcome. However, recent studies have demonstrated results comparable to those of recipients without HIV infections. They have shown that HIV-positive patients maintained on HAART mount an immune response. Immunosuppressive agents are chosen to minimize aggravation of HIV infection, bearing in mind the potential side effects of the combination of HAART and immunosuppressive drugs. Herein we have reported the case of a 43-year-old HIV- and hepatitis C virus-infected woman with preserved immune function who received a cadaveric kidney transplant and developed an acute humoral rejection, which was successfully treated with Rituximab.
在高效抗逆转录病毒疗法(HAART)时代之前,由于预后不佳,肾移植不被视为感染人类免疫缺陷病毒(HIV)患者的选择。然而,最近的研究表明其结果与未感染HIV的受者相当。这些研究表明,接受HAART治疗的HIV阳性患者会产生免疫反应。选择免疫抑制剂以尽量减少HIV感染的加重,同时要考虑到HAART与免疫抑制药物联合使用的潜在副作用。在此,我们报告了一例43岁感染HIV和丙型肝炎病毒且免疫功能保留的女性患者,她接受了尸体肾移植并发生了急性体液排斥反应,该反应通过利妥昔单抗成功治疗。